Sartorius Stedim Biotech opens new center for bioprocess innovation in Massachusetts

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

René Fáber, CEO of Sartorius Stedim Biotech, said: ”Cell and gene therapies and other novel treatments offer promising solutions for patients with previously incurable diseases. However, these modalities are still in their infancy and often require the development of new manufacturing processes, in order to become more efficient and less costly. This cutting-edge innovation center enables us to leverage our bioprocessing tools and workflows expertise, ultimately accelerating and simplifying our customers’ path to clinical trials” .

In 2025, Sartorius Stedim Biotech will add two multi-modality GMP suites, operating on Sartorius workflows and equipment.

Maurice Phelan, President of Sartorius North America, said: ”The Greater Boston area is home to an unparalleled ecosystem that fosters innovation, collaboration, and growth. As a global hub for biotechnology and life sciences, it offers access to world-renowned academic institutions, cutting-edge research facilities, and a highly skilled workforce. Moreover, the region’s robust network of venture capital firms and industry partnerships provides ample opportunities for strategic collaborations. This is an ideal time and a great place to launch these capabilities which are so critical to the success of our customers.”

Yvonne Hao, Massachusetts Secretary of Economic Development, said: ”Massachusetts is the global epicenter of life sciences because of companies like Sartorius. This new center will serve as a hub that encourages open collaboration and creates comprehensive research pathways for experts. We look forward to this company’s continued success, and we are grateful for their work.”